Sintilimab-induced autoimmune diabetes: A case report and review of the literature

doi:10.12998/wjcc.v10.i4.1263

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 4

This Article

(278)

(252)

(0)

(10)

(2)

(4938)

(5)

Peer-Review Report of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Case Report

World J Clin Cases. Feb 6, 2022; 10(4): 1263-1277
Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1263

Table 4 Characteristics of patients with diabetes induced by immune checkpoint inhibitors

Reported cases	n (%)
Tumor types
Melanoma	13/36 (36.1)
NSCLC	8/36 (22.2)
Renal cell carcinoma	2/36 (5.6)
Squamous cell carcinoma	3/36 (8.3)
Other cancers	10/36 (27.8)
ICBs
Anti PD-1	19/ 36 (52.7)
Nivolumab	12
Pembrolizumab	6
Sintilimab	1
Anti PD-L1	8/ 36 (22.2)
Avelumab	2
Atezolizumab	5
Durvalumab	1
Anti PD-1+CTLA-4	9/ 36 (25.0)
Nivolumab + ipilimumab	8
Pembrolizumab + ipilimumab	1
Demographic data
Sex (F/M)	16/20
Average age (yr)	58.8
Time of diagnosis after start of (w)	14.6
Presentation
DKA	29/36 (80.6)
Hyperglycemia Ketonuria	8/36 (22.2)
HbA1c, % (avg)	7.8 26/36
Relevant history
T2DM	3/36 (8.3)
Hypothyroidism	2/36 (5)
Family history of T1DM	2/36 (5)
None	29/36 (80.5)
Antibodies
GAD+	18/36 (50)
IA-2+	4/36 (10)
ZnT8+	2/36 (5)
Negative	12/36 (33.3)

NSCLC: Non-small cell lung cancer; PD-L1: Programmed death-ligand 1; DKA: Diabetic ketoacidosis; T1DM: Type 1 diabetes mellitus; T2DM: Type 2 diabetes mellitus; GAD: Anti-glutamic acid decarboxylase antibody.

Full Size Table

Citation: Yang J, Wang Y, Tong XM. Sintilimab-induced autoimmune diabetes: A case report and review of the literature. World J Clin Cases 2022; 10(4): 1263-1277
URL: https://www.wjgnet.com/2307-8960/full/v10/i4/1263.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i4.1263

Yang J, Wang Y, Tong XM. Sintilimab-induced autoimmune diabetes: A case report and review of the literature. World J Clin Cases 2022; 10(4): 1263-1277 [PMID: 35211559 DOI: 10.12998/wjcc.v10.i4.1263]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.